These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 29973784)

  • 1. Candidate Gene in Predicting In Vivo Ovarian Cancer Response to Combination Therapy with Paraplatin and Paclitaxel.
    Mirhashemi R; Arena JF; Frudakis T; Lambrou N; Arboleda J; Hunt M; Medranda M; Averette H; Penalver M
    ScientificWorldJournal; 2002; 2():19-20. PubMed ID: 29973784
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft.
    Weitman S; Mangold G; Marty J; Dexter D; Hilsenbeck S; Rake J; Juniewicz P; Von Hoff D
    Cancer Chemother Pharmacol; 1999; 43(5):402-8. PubMed ID: 10100596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel in the treatment of ovarian cancer.
    Kavanagh JJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):73-81. PubMed ID: 12108900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.
    Markman M; Zanotti K; Webster K; Belinson J; Rose P
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):34-5. PubMed ID: 12800604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.
    Lavarino C; Pilotti S; Oggionni M; Gatti L; Perego P; Bresciani G; Pierotti MA; Scambia G; Ferrandina G; Fagotti A; Mangioni C; Lucchini V; Vecchione F; Bolis G; Scarfone G; Zunino F
    J Clin Oncol; 2000 Dec; 18(23):3936-45. PubMed ID: 11099323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)].
    Yasuda M; Kimura E; Ochiai K; Tada S; Udagawa Y; Aoki D; Nozawa S; Kikuchi Y; Kita T; Nishida M; Tsunoda H
    Gan To Kagaku Ryoho; 2001 Apr; 28(4):493-8. PubMed ID: 11329783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
    Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
    Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway.
    Ueno NT; Bartholomeusz C; Herrmann JL; Estrov Z; Shao R; Andreeff M; Price J; Paul RW; Anklesaria P; Yu D; Hung MC
    Clin Cancer Res; 2000 Jan; 6(1):250-9. PubMed ID: 10656456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
    Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Yang X; Feng Y; Gao Y; Shen J; Choy E; Cote G; Harmon D; Zhang Z; Mankin H; Hornicek FJ; Duan Z
    Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo.
    Voloshin T; Munster M; Blatt R; Shteingauz A; Roberts PC; Schmelz EM; Giladi M; Schneiderman RS; Zeevi E; Porat Y; Bomzon Z; Urman N; Itzhaki A; Cahal S; Kirson ED; Weinberg U; Palti Y
    Int J Cancer; 2016 Dec; 139(12):2850-2858. PubMed ID: 27561100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer.
    Tsujioka H; Fukami T; Yotsumoto F; Ueda T; Hikita S; Takahashi Y; Kondo H; Kuroki M; Miyamoto S
    Anticancer Res; 2011 Jul; 31(7):2461-5. PubMed ID: 21873160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
    Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
    Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
    Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
    Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer.
    Fountzilas G; Athanassiades A; Papadimitriou V; Dimopoulos MA; Bafaloukos D; Aravantinos G; Nicolaides C; Kalofonos H; Papakostas P; Xiros N; Razi E
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):45-8. PubMed ID: 9516604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-exposed ovarian cancer cells induce cancer‑specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.
    Kim JE; Jang MJ; Jin DH; Chung YH; Choi BS; Park GB; Kim YS; Kim S; Hur DY; Hung CF; Kim D
    Int J Oncol; 2014 May; 44(5):1716-26. PubMed ID: 24573741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum levels in murine tumor following intraperitoneal administration of cisplatin or paraplatin.
    Douple EB; Totten MD; Spencer F
    NCI Monogr; 1988; (6):129-32. PubMed ID: 3281028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.